Pictet Asset Management (Switzerland)’s Apellis Pharmaceuticals APLS Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$84.6M	Buy	928,624 +478,585	+106%	+$41.3M	0.1%	214
2023 Q1	$29.7M	Buy	450,039 +4,334	+1%	+$250K	0.04%	377
2022 Q4	$23M	Sell	445,705 -541,862	-55%	-$28.7M	0.03%	417
2022 Q3	$67.5M	Buy	987,567 +9,909	+1%	+$586K	0.1%	233
2022 Q2	$44.2M	Buy	977,658 +79,702	+9%	+$3.63M	0.06%	303
2022 Q1	$45.6M	Buy	897,956 +251,597	+39%	+$11.1M	0.05%	332
2021 Q4	$30.6M	Buy	+646,359	New	+$25.4M	0.03%	436

Other funds holding APLS

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s APLS Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Apellis Pharmaceuticals (APLS) stake by 106% in Q2 2023, buying an estimated $41.3M and bringing the position to 928,624 shares worth $84.6M. The position accounts for 0.1% of the portfolio, ranked #214.

Pictet Asset Management (Switzerland) first reported a position in APLS in Q4 2021 and has held it in 7 quarters since. 317 funds tracked by Wall St. Rank hold APLS as of Q2 2023.

Pictet Asset Management (Switzerland) held 928,624 shares of Apellis Pharmaceuticals worth $84.6M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 478,585 Apellis Pharmaceuticals shares in Q2 2023, an estimated $41.3M.
Apellis Pharmaceuticals made up 0.1% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #214 holding.
Pictet Asset Management (Switzerland) first reported a position in Apellis Pharmaceuticals in Q4 2021 and has held it in 7 quarters since.
317 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.